CRP and major depressive disorder: The primary objective of this study is to evaluate whether a 12-week celecoxib treatment added to TAU (defined as SSRI or SNRI pharmacotherapy) is more effective in reducing depressive symptoms as measured with the Inventory of Depressive Symptomatology – self report (IDS 30-item self-report (Rush et al., 2006; Rush et al., 1986; Rush et al., 1996; Rush et al., 2011)) than placebo in patients aged 18–65yr with Major Depressive Disorder (MDD) and IMD characteristics (≥6 IDS atypical, energy related symptoms (Lamers et al., 2013) and circulating CRP>1 mg/l) during 12-week follow up.